Dr Reddy’s Laboratories Ltd has launched Fesoterodine Fumarate extended-release tablets, a therapeutic generic equivalent to Toviaz (fesoterodine fumarate) extended-release tablets in the U.S. market following the approval by the U.S. Food and Drug Administration (USFDA).
The Toviaz brand had US sales of approximately $211 million MAT for the most recent twelve months ending in May according to IQVIA., the company said in a release.
Dr Reddy’s Fesoterodine Fumarate tablets are available in 4 mg and 8 mg Tablets, each in bottle count sizes of 30.
Toviaz is a trademark of Pfizer Inc. Fesoterodine fumarate extended-release tablets are indicated for the treatment of: • Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.